Bio Plus Co., Ltd
Financials
Valuation Metrics
Bio Plus Co., Ltd's Market Cap is ₩1994B. At end of 2025 it was ₩3101B. Ranked #801 of 2,410 in KR market (top 33%), #359 of 1,631 on KOSDAQ (top 22%), #24 of 94 in Health Care Equipment & Services (top 26%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 199.41B KRW | KR#801/2,410 Sec#24/94 |
| Revenue | 99.15B KRW | KR#1,424/2,410 Sec#37/94 |
| Net Income | 19.79B KRW | KR#709/2,410 Sec#17/94 |
| Total Assets | 296.60B KRW | KR#1,045/2,410 Sec#23/94 |
| Net Assets | 200.33B KRW | KR#946/2,410 Sec#24/94 |
| Employees | 155 | KR#1,293/2,410 Sec#42/94 |
| Value | ||
| P/E | 10.08x | KR#876/2,410 Sec#28/94 |
| P/B | 1.00x | KR#1,539/2,410 Sec#44/94 |
| PEG | 0.06x | KR#337/2,410 Sec#15/94 |
| P/S | 2.01x | KR#1,860/2,410 Sec#54/94 |
| EV/EBITDA | 13.88x | KR#858/2,410 Sec#28/94 |
| FCF Yield | -15.97% | KR—/2,410 Sec—/94 |
| Profitability | ||
| ROE | 9.88% | KR#628/2,410 Sec#27/94 |
| ROA | 6.67% | KR#555/2,410 Sec#28/94 |
| Op. Margin | 17.89% | KR#204/2,410 Sec#18/94 |
| Revenue Growth | 11.20% | KR#838/2,410 Sec#44/94 |
| Earnings Growth | 175.84% | KR#264/2,410 Sec#14/94 |
| Financial Health | ||
| Debt Ratio | 48.06% | KR#934/2,410 Sec#51/94 |
| Total Debt | 66.93B KRW | KR#887/2,410 Sec#20/94 |
| FCF | -31.84B KRW | KR#1,996/2,410 Sec#76/94 |
| Cash | 20.18B KRW | KR#1,250/2,410 Sec#33/94 |
| Current Ratio | 0.95x | KR#1,777/2,410 Sec#80/94 |
| Net Debt/EBITDA | 2.64x | KR#887/2,410 Sec#35/94 |
| Dividend | ||
| Div. Yield | 2.18% | KR#885/2,410 Sec#20/94 |
| Div. Growth | 40.00% | KR#288/2,410 Sec#14/94 |
| Performance | ||
| 1Y Return | -48.24% | KR#1,966/2,410 Sec#73/94 |
| 1M Return | -14.53% | KR#1,199/2,410 Sec#44/94 |
| From 52W High | -52.00% | KR#1,248/2,410 Sec#47/94 |
| 1Y MDD | -50.46% | KR#979/2,410 Sec#36/94 |
| Trading | ||
| Volume | 69,699 shares | KR#542/2,410 Sec#22/94 |
| Trading Value | 224.7M KRW | KR#894/2,410 Sec#30/94 |
| Foreign Own. | 3.12% | KR#1,246/2,410 Sec#42/94 |
| Per Share | ||
| EPS | 321 KRW | KR#1,146/2,410 Sec#35/94 |
| BPS | 3,250 KRW | KR#1,814/2,410 Sec#53/94 |
Company Info
Established in 2003 and rebranded in 2013, the company expanded its business in 2025 by establishing BioPlus USA Inc. and acquiring equity. It primarily focuses on the research, development, manufacturing, and sales of hyaluronic acid-based medical devices and Bio Cosmetic products, while also concentrating on developing next-generation botulinum toxin and obesity treatments. Employing a technology-driven strategy, the company exports to over 70 overseas countries and is accelerating its global market entry by establishing an overseas subsidiary and local production facilities in China. BioPlus was established in 2003 and is headquartered in Gyeonggi-do, Seongnam-si.